BioCentury
ARTICLE | Clinical News

Gamma interferon data

March 3, 1997 8:00 AM UTC

Positive Phase II results in severe atopic dermatitis were presented at the meeting of the American Academy of Allergy, Asthma and Immunology in San Francisco. The data from the open-label trial in adults and children support previous findings of safety and efficacy.

The data included 14 patients who had previously completed a 12-week, double-blind trial; 8 were under age 16. All went on to complete at least 22 months of open label treatment. All parameters of clinical severity were improved after two years, by statistically significant amounts. Efficacy measures included total area involved, and severity of redness, swelling, itching, scratch marks, scaling, and accentuation of skin markings. Amount of skin affected declined from 62 percent to 19 percent over the trial. Side effects were minimal. ...